Literature DB >> 16859622

The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis.

Mazen Elyan1, Muhammad Asim Khan.   

Abstract

Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-alpha inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859622     DOI: 10.1007/s11926-006-0005-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  47 in total

1.  Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2005-06

2.  Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2006-03-10       Impact factor: 2.980

3.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Authors:  David Y Graham; Naurang M Agrawal; Donald R Campbell; Marian M Haber; Cyndy Collis; Nancy L Lukasik; Bidan Huang
Journal:  Arch Intern Med       Date:  2002-01-28

4.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

6.  Experts' beliefs on physiotherapy for patients with ankylosing spondylitis and assessment of their knowledge on published evidence in the field. Results of a questionnaire among international ASAS members.

Authors:  B Mihai; S van der Linden; R de Bie; G Stucki
Journal:  Eura Medicophys       Date:  2005-06

7.  A comparative study of diclofenac and sulindac in ankylosing spondylitis.

Authors:  A M Nahir; Y Scharf
Journal:  Rheumatol Rehabil       Date:  1980-08

8.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

Review 9.  Pharmacological treatment of ankylosing spondylitis: a systematic review.

Authors:  Pauline Boulos; Maxime Dougados; Stuart M Macleod; Elke Hunsche
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 10.  Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Authors:  Jonathan J Deeks; Lesley A Smith; Matthew D Bradley
Journal:  BMJ       Date:  2002-09-21
View more
  4 in total

1.  Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.

Authors:  Seyed Shahabeddin Mortazavi-Jahromi; Sepideh Nazeri; Fahimeh Jafarnezhad-Ansariha; Mona Oraei; Abbas Mirshafiey
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Effects of dynamic exercise on circulating IGF-1 and IGFBP-3 levels in patients with rheumatoid arthritis or ankylosing spondylitis.

Authors:  Saliha Karatay; Kadir Yildirim; Meltem Alkan Melikoglu; Fatih Akcay; Kazim Senel
Journal:  Clin Rheumatol       Date:  2007-02-24       Impact factor: 2.980

3.  A retrospective study of transcutaneous electrical nerve stimulation for chronic pain following ankylosing spondylitis.

Authors:  Fu-Chun Chen; Zhen-Ling Jin; Deng-Feng Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 4.  Effectiveness of Physiotherapy in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Authors:  Luca Pontone Gravaldi; Francesca Bonetti; Simona Lezzerini; Fernando De Maio
Journal:  Healthcare (Basel)       Date:  2022-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.